Meta-analytic Phase I clinical trial
A meta-analytic Phase I clinical trial formally pools evidence from prior Phase I studies — using Bayesian or frequentist meta-analysis — to construct an informative prior (or summary estimate) for dose-toxicity relationships before or during a new first-in-human or early-phase study. The approach increases statistical efficiency, reduces the number of patients exposed to subtherapeutic or toxic doses, and accelerates dose selection by systematically leveraging all relevant historical dose-finding data.
Rekod sumber
Petikan disalin secara verbatim daripada rekod sumber kaedah. Tiada pengesahan peringkat tuntutan disimpulkan daripadanya.
- Neuenschwander, B., Capkun-Niggli, G., Branson, M., & Spiegelhalter, D. J. (2010). Summarizing historical information on controls in clinical trials. Clinical Trials, 7(1), 5–18. · DOI 10.1177/1740774509356002
- Jaki, T., Clive, S., & Weir, C. J. (2013). Principles of dose finding studies in cancer: a comparison of trial designs. Cancer Chemotherapy and Pharmacology, 71(5), 1107–1114. · DOI 10.1007/s00280-012-2059-8
Tuntutan yang dikurasi
Tuntutan disimpan dalam lejar bukti, setiap satu dengan penilaiannya sendiri.
Pandangan ini tidak mencipta penilaian tuntutan apabila lejar tiada.
Kaedah berkaitan
Dijana daripada graf kaedah dan ditunjukkan sebagai perhubungan yang dicadangkan mesin — tiada tuntutan bukti disimpulkan.